Please refer letter in relation to reappointment of Managing Director-Dr Ashish Rawandale.

Management Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹21.71

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.1%+0.8% vs market

Healthcare Service Provider peers, median of 23sector+0.1%-0.3% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3-1.1+0.8+0.1-0.3

Next day

+2.5-0.3+2.8+1.5+1.0

+2.3-0.4+2.7-0.6+2.9

+5.4+0.3+5.2+0.0+5.4

+1.3+0.8+0.5+1.3+0.0

+1.1+0.7+0.4+1.2-0.1

+1.3+1.4-0.1+1.7-0.4

15d

+1.3+4.7-3.4+3.3-1.9

-2.6+0.7-3.2+3.9-6.4

-6.7+6.4-13.1+6.1-12.8

-13.2+2.7-15.8+8.2-21.4

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tejnaksh Healthcare Ltd has informed BSE about the reappointment of Dr. Ashish Rawandale as Chairman & Managing Director for a further period of 5 years, effective 27th March 2025. The reappointment is subject to shareholder approval at the company's next general meeting. Dr. Rawandale is the promoter of the company and a renowned urologist holding multiple records in Guinness, Limca and Asia Book of Records, along with 150+ academic publications. His spouse, Dr. Preeti Rawandale, serves as a Non-Executive Director from the promoter group. The intimation was filed on 19 May 2025 under SEBI LODR Regulation 30.

Likely market impact

This is a routine reappointment of the existing promoter-MD, ensuring leadership continuity for the next five years. No material change in strategy or governance is expected, though shareholder approval at the next general meeting is still required to formalize it.